Cell-free deoxyribonucleic acid analysis in preimplantation genetic testing

Area of Science:

• Reproductive Medicine
• Genetics
• Embryology

Background:

• Preimplantation genetic testing (PGT) is crucial for selecting viable embryos during in vitro fertilization (IVF) to ensure healthy pregnancies.
• Current PGT methods require invasive trophectoderm biopsy, increasing IVF costs and potential pregnancy complications.
• A need exists for noninvasive embryo screening to mitigate risks and reduce treatment expenses.

Approach:

• This review examines studies evaluating the concordance of noninvasive PGT using cell-free DNA (cfDNA) with traditional methods like trophectoderm biopsy or whole blastocyst analysis.
• Analysis focuses on cfDNA found in embryo culture medium, released during later preimplantation development stages.
• The review synthesizes data on the accuracy of cfDNA analysis for detecting chromosomal abnormalities in embryos.

Key Points:

• Cell-free DNA in culture medium offers a potential noninvasive avenue for PGT.
• Studies report promising concordance rates between cfDNA analysis and biopsy-based PGT for aneuploidy detection.
• Early clinical applications of noninvasive PGT demonstrate feasibility.

Conclusions:

• Noninvasive PGT using cfDNA is a developing strategy with significant potential to improve IVF outcomes.
• Further research is necessary to validate its efficacy for detecting structural rearrangements and monogenic disorders.
• This approach could revolutionize embryo selection by offering a safer, potentially more accessible alternative to invasive PGT.